Literature DB >> 10825525

Radiosurgery for bilateral neurinomas associated with neurofibromatosis type 2.

Y Kida1, T Kobayashi, T Tanaka, Y Mori.   

Abstract

OBJECTIVE: The clinical course of bilateral acoustic tumors associated with neurofibromatosis (NF2) is generally troublesome, and no definite treatment strategy has been established. Follow-up results of bilateral acoustic tumors after radiosurgery are reported herein.
METHODS: The current indications for radiosurgery are 1) a growing tumor less than 30 mm in mean diameter, 2) the ipsilateral ear has no serviceable hearing, and 3) there is risk of brain stem compression or brain stem dysfunction. Twenty cases of bilateral acoustic tumors were treated with the gamma knife, including 7 males and 13 females. The mean age was 38.2 years and the mean tumor size 24.4 mm. The tumors were treated with mean maximum and marginal doses of 26.8 Gy and 13.0 Gy, respectively. Among them, 12 patients had profound hearing loss in the ipsilateral (treated) ear, but the other 8 had serviceable hearing.
RESULTS: Tumors treated with radiosurgery showed central necrosis in 60% of the cases at 6 months and in 70% at 9 months after radiosurgery. Thereafter, the tumors often demonstrated slow regression. The rate of tumor shrinkage was 20% at 12 months, 35% at 24 months, and almost 60% at 36 months. At the last follow-up (mean 33.6 months), the tumors demonstrated shrinkage in 50% and tumor control in 100%. The contralateral tumors were stable in 12 (60%) and enlarged in 8 (40%). Preservation of serviceable hearing ipsilaterally was obtained in 33.3%. Deterioration of ipsilateral facial nerve function, either in the natural course or as a complication, occurred in 10%.
CONCLUSIONS: Because of good tumor control and tumor shrinkage as well as an acceptable complication rate, radiosurgery should be incorporated in the treatment strategy for bilateral acoustic tumors associated with NF2.

Entities:  

Mesh:

Year:  2000        PMID: 10825525     DOI: 10.1016/s0090-3019(00)00174-9

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  12 in total

Review 1.  Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes.

Authors:  D G R Evans; J M Birch; R T Ramsden; S Sharif; M E Baser
Journal:  J Med Genet       Date:  2005-09-09       Impact factor: 6.318

Review 2.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

3.  Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors.

Authors:  Michael S Dirks; John A Butman; H Jeffrey Kim; Tianxia Wu; Keaton Morgan; Anne P Tran; Russell R Lonser; Ashok R Asthagiri
Journal:  J Neurosurg       Date:  2012-04-13       Impact factor: 5.115

4.  Tumor control and hearing preservation after Gamma Knife radiosurgery for vestibular schwannomas in neurofibromatosis type 2.

Authors:  Manish Singh Sharma; Rakesh Singh; Shashank S Kale; Deepak Agrawal; Bhawani Shankar Sharma; Ashok Kumar Mahapatra
Journal:  J Neurooncol       Date:  2010-04-20       Impact factor: 4.130

5.  [Stereotactic radiosurgery and fractionated stereotactic radiotherapy of acoustic neuromas].

Authors:  F Unger; K Dominikus; K Haselsberger
Journal:  HNO       Date:  2011-01       Impact factor: 1.284

6.  Neurofibromatosis 2: Primary Modality of Hearing Rehabilitation with Cochlear Implant.

Authors:  Dathathri Anantaramaiah Halyur; Praveen H Rayanagoudar; Apurva Kumar; Sunil Narayan Dutt
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2021-06-15

7.  Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis.

Authors:  J G Rowe; M W R Radatz; L Walton; T Soanes; J Rodgers; A A Kemeny
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

8.  Factors influencing overall survival rates for patients with pineocytoma.

Authors:  Aaron J Clark; Michael E Sughrue; Michael E Ivan; Derick Aranda; Martin J Rutkowski; Ari J Kane; Susan Chang; Andrew T Parsa
Journal:  J Neurooncol       Date:  2010-05-12       Impact factor: 4.130

9.  Clinical outcome of neurofibromatosis type 2-related vestibular schwannoma: treatment strategies and challenges.

Authors:  Byung Sup Kim; Ho Jun Seol; Jung-Il Lee; Hyung Jin Shin; Kwan Park; Doo-Sik Kong; Do-Hyun Nam; Yang-Sun Cho
Journal:  Neurosurg Rev       Date:  2016-05-04       Impact factor: 3.042

Review 10.  Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.

Authors:  Scott R Plotkin; Chris Halpin; Jaishri O Blakeley; William H Slattery; D Bradley Welling; Susan M Chang; Jay S Loeffler; Gordon J Harris; A Gregory Sorensen; Michael J McKenna; Fred G Barker
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.